<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670488</url>
  </required_header>
  <id_info>
    <org_study_id>2206-002</org_study_id>
    <secondary_id>2008_513</secondary_id>
    <nct_id>NCT00670488</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study With MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors (2206-002)</brief_title>
  <official_title>A Phase I Dose Escalation Study of Oral MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with locally advanced or metastatic solid tumors who have failed
      standard therapy or no other standard therapy exists.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize safety and tolerability of MK2206 by monitoring incidence rate of adverse experiences</measure>
    <time_frame>study duration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Define dose-limiting toxicities (DLT) and maximum tolerated dose by monitoring incidence of protocol-defined DLT</measure>
    <time_frame>Day 1 - Day 28 (Cycle 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess pharmacokinetic (PK) profile of MK2206 by determining parameters such as AUC, Cmax, Tmax</measure>
    <time_frame>Day 1 - Day 28 (Cycle 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the recommended Phase II dose of MK2206 by assessing safety/tolerability, PK and pharmacodynamics of MK2206</measure>
    <time_frame>study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate target engagement following treatment with MK2206 by assessing pharmacodynamics in tissue</measure>
    <time_frame>Day 1 - Day 28 (Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate anti-tumor activity following treatment with MK2206 by assessing tumor response and clinical benefit</measure>
    <time_frame>every 56 days, beginning on Day 63</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Locally Advanced Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>QOD Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK2206 every other day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QW Schedule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK2206 once weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK2206</intervention_name>
    <description>Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 30 mg, 60 mg, 75 mg, and 90 mg on a schedule of once daily every other day in repeating 4 week cycles.</description>
    <arm_group_label>QOD Schedule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK2206</intervention_name>
    <description>Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 90 mg, 135 mg, 200 mg, 250 mg, and 300 mg on a schedule of once weekly in repeating 4 week cycles.</description>
    <arm_group_label>QW Schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have confirmed locally advanced or metastatic solid tumors that have
             failed to respond to standard therapy, have gotten worse or have come back after
             existing therapy

          -  Has normal organ function; is no greater than 2 on the ECOG Performance Scale

          -  Has a negative blood or urine pregnancy test within 72 hours of receiving the first
             dose of study drug if patient is female

          -  Is able to swallow capsules and has no surgical or bodily condition that will prevent
             the patient from swallowing and absorbing oral medications on an ongoing basis

        Exclusion Criteria:

          -  Patient has had chemotherapy, radiotherapy, biological therapy or surgery within 4
             weeks of starting the study and has not recovered from adverse events caused by the
             treatment

          -  Is currently participating or has participated in a study with an investigational
             compound or device within 30 days

          -  Has a primary central nervous system tumor

          -  Has a history or current evidence of heart disease, slow heart rate or untreated high
             blood pressure

          -  Is a known diabetic who is taking insulin or oral antidiabetic therapy

          -  Is pregnant or breastfeeding or planning to become pregnant during the study

          -  Is HIV-positive

          -  Has known history of Hepatitis B or C or active Hepatitis A

          -  Is receiving treatment with oral corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011 Dec 10;29(35):4688-95. doi: 10.1200/JCO.2011.35.5263. Epub 2011 Oct 24.</citation>
    <PMID>22025163</PMID>
  </results_reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>April 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2008</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

